Amir T. Fathi MD [slides]- IDH 1/2-Mutant AML Treatment Acute Myelogenous Leukemia 1 Min Read7 Amir T. Fathi MD Associate Professor of Medicine, Harvard Medical School Program Director, Center for Leukemia- Massachusetts General Hospital Join…
INDIGO Trial Understanding IDH Mutations in Grade 2 Gliomas: Role and Significance Explored Brain 3 Mins Read6 Dr. Katherine Peters from Duke University Medical Center discussed the current treatments and their limitations for low-grade glioma patients with…
